Kymera Therapeutics Inc (KYMR : NASDAQ)
Common Stock
$110.85
USD
-1.78 (-1.58%)
Last updated: 2026-10-22
Follow KYMR
KYMR
Kymera Therapeutics Inc
WealthAwesomePerformance
1 Day
-1.58%
1 Week
+2.51%
1 Month
-9.18%
YTD
+23.30%
Key Statistics
Market Cap
$9.26B
52W High
$130.05
52W Low
$55.66
P/E Ratio
-
50 Day MA
$115.15
200 Day MA
$94.90
Beta
1.98
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/22/2026 | $111.43 | $113.74 | $110.13 | $110.85 | $110.85 | 850,250 |
| 10/21/2026 | $113.38 | $115.75 | $112.52 | $112.63 | $112.63 | 1,056,300 |
| 10/20/2026 | $108.75 | $115.28 | $108.49 | $113.46 | $113.46 | 688,980 |
| 10/19/2026 | $106.56 | $109.16 | $105.10 | $108.07 | $108.07 | 681,557 |
| 10/16/2026 | $108.19 | $108.59 | $104.39 | $104.78 | $104.78 | 488,700 |
| 10/15/2026 | $106.75 | $110.68 | $104.63 | $108.14 | $108.14 | 820,992 |
| 10/14/2026 | $106.39 | $108.08 | $105.58 | $106.83 | $106.83 | 1,025,615 |
| 10/13/2026 | $110.83 | $112.06 | $106.52 | $106.68 | $106.68 | 764,398 |
| 10/12/2026 | $111.61 | $113.13 | $110.52 | $112.08 | $112.08 | 488,519 |
| 10/9/2026 | $109.54 | $115.81 | $107.46 | $112.40 | $112.40 | 1,305,200 |
Analyst Price Targets
Based on 24 analysts covering KYMR · as of Oct 14, 2026
Wall Street analysts forecast KYMR stock price to rise 25.7% over the next 12 months.
Consensus
Strong Buy4.63 / 5.00
Avg. Target
US$139.35
+25.7% Upside
Previously US$139.32 on Oct 12, 2026
Current Price
US$110.85
Last close
Analyst Breakdown (24 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on KYMR's historical volatility
30-Day Vol
40.3%
Annualized
90-Day Vol
51.9%
Annualized
Trend (90d)
+21.8%
Annualized drift
90d Mean
US$119.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$113.76 | US$99.01 – US$130.71 |
| 60 trading days | US$116.75 | US$95.93 – US$142.09 |
| 90 trading days | US$119.81 | US$94.19 – US$152.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Financials
- Revenue (TTM)
- $105.00M
- EBITDA
- $-339.89M
- Profit Margin
- -285.33%
- ROE (TTM)
- -24.15%
- EPS (Diluted)
- -3.25
- Book Value
- 18.23
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About KYMR.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| HCAI | Huachen AI Parking Management Technology Holding Co Ltd | $3.30 | +1365.19% |
| NVNI | Nvni Group Limited Ordinary Shares | $0.53 | +1224.94% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +227.94% |
| TANH | Tantech Holdings Ltd | $24.83 | +181.84% |
| SHFS | SHF Holdings Inc | $0.34 | +122.37% |
| XLAB | Exascale Labs Holdings Inc. Class A Common Stock | $4.71 | +73.16% |
| STAK | STAK Inc. Ordinary Shares | $1.67 | +67.00% |
| PASW | Ping An Biomedical Co., Ltd. | $5.40 | +46.85% |
KYMR.US news timeline
1 article covering KYMR.US, most recent first
Latest